GO:0070934 CRD-mediated mRNA stabilization Guide

GO:0070934, CRD-mediated mRNA stabilization, is a biological process in which one or more RNA-binding proteins associate with a sequence in the open reading frame called the coding region instability determinant (CRD) and thereby stabilize the mRNA. This is a post-transcriptional regulatory mechanism: instead of changing transcription, it changes the half-life of an already-made transcript, so the amount of protein produced can rise or fall without any change in promoter activity. The concept emerged from studies of unstable transcripts such as c-myc, whose coding region contains elements that target the mRNA for rapid decay unless protected by specific RNA-binding proteins. For researchers, CRD-mediated mRNA stabilization matters because it sits at the intersection of RNA biology, cancer cell biology and gene regulation. The founding example is the control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs, which showed that a protein complex can recognize a CRD and shield the transcript from degradation. More recent work has extended the theme of post-transcriptional control to other cancer contexts, including CARMN regulation in cervical cancer through autophagic flux blockade and MAPK cascade inhibition, and to proteomic and bioinformatic dissection of resistance phenotypes in prostate cancer cells. Because the CRD is a sequence element rather than a single gene, the process is best studied as an interaction between cis-acting RNA elements and trans-acting RNA-binding proteins. This makes it an attractive target for CRISPR-based functional genomics: deleting or mutating the protein factors, or editing the CRD itself, can reveal whether a given transcript's stability is causally linked to a disease phenotype.

CRD-mediated mRNA stabilization is an mRNA stabilization process in which one or more RNA-binding proteins associate with a sequence in the open reading frame called the coding region instability determinant (CRD). In plain terms, the CRD is a built-in instability signal inside the protein-coding part of an mRNA, and when specific RNA-binding proteins bind it, the mRNA is protected and survives longer. The QuickGO synonym for this process is coding region determinant-mediated mRNA stabilization.

CRD-mediated mRNA stabilization is important because it provides a fast, reversible way for cells to control protein output from unstable transcripts without altering transcription. The c-myc example established that a coding region element can act as a decay signal and that RNA-binding protein complexes such as IGF2BP1-associated RNPs can counteract that signal. Because many oncogenes and growth-control transcripts are inherently unstable, CRD-dependent stabilization can shift the balance toward accumulation of proteins that drive proliferation and survival. Understanding this process therefore informs cancer biology, RNA therapeutics and the interpretation of post-transcriptional regulatory networks in disease.

The following genes and proteins have been experimentally linked to CRD-mediated mRNA stabilization or to the broader post-transcriptional regulatory context in which this process operates.

CRD-mediated mRNA stabilization is regulated by the availability and activity of the RNA-binding proteins that recognize the CRD. In the c-myc system, IGF2BP1-associated cytoplasmic RNPs control c-myc mRNA stability, meaning that changes in the composition or abundance of these RNPs can shift the balance between stabilization and decay. More broadly, post-transcriptional regulation of transcripts such as CARMN in cervical cancer involves autophagic flux blockade and MAPK cascade inhibition, and proteomic and bioinformatic analyses of bortezomib resistance in prostate cancer cells highlight how cellular state can reshape post-transcriptional and protein-level networks. These observations indicate that CRD-mediated stabilization is not a fixed property of a transcript but a regulated interaction that depends on cellular context.

CRD-mediated mRNA stabilization is most directly linked to cancer through the control of unstable oncogenic transcripts. The c-myc mRNA is a classic example, where IGF2BP1-associated cytoplasmic RNPs control its stability via the coding region. Because c-myc drives proliferation and survival, changes in its mRNA half-life can influence tumor cell behavior. More recent work on CARMN in cervical cancer has shown that transcriptional and post-transcriptional regulation of this transcript is linked to anti-tumor function through autophagic flux blockade and MAPK cascade inhibition, illustrating how post-transcriptional mechanisms contribute to cancer phenotypes.

Post-transcriptional regulation can contribute to acquired drug resistance. Comparative proteomic and bioinformatic analysis of bortezomib resistance in prostate cancer cells has been used to identify proteins and pathways that change during resistance acquisition. Although this study is not a direct analysis of CRD-mediated stabilization, it provides a framework for asking whether mRNA stability changes contribute to the resistant phenotype, and it highlights the value of combining proteomics with RNA-level analysis.

CRD-mediated stabilization is one node in a larger network of RNA-protein interactions that influence cancer progression. For example, LRRC59 promotes oral squamous cell carcinoma progression by interacting with SRP pathway components and enhancing secretion of CKAP4-containing exosomes. While this is not a CRD-specific mechanism, it demonstrates how RNA-binding and protein-trafficking pathways can be dissected in cancer models, providing a template for studying CRD-dependent stabilization in similar systems.

The most direct way to study CRD-mediated mRNA stabilization is to measure the half-life of a CRD-containing transcript after transcription is halted. In the c-myc system, this approach was used to show that IGF2BP1-associated RNPs control c-myc mRNA stability. Researchers can combine this with reporter constructs in which the CRD is placed upstream of a reporter gene, allowing the contribution of the CRD to be isolated from other regulatory elements.

Because the process is defined by RNA-binding protein association with the CRD, RNA immunoprecipitation is a key method. It can identify which transcripts are bound by a given RNA-binding protein and whether the CRD is enriched in the bound fraction. The characterization of IGF2BP1-associated cytoplasmic RNPs that control c-myc mRNA stability provides a template for this type of analysis.

CRISPR knockout, point mutation and knock-in models allow causal testing of CRD-mediated stabilization. Deleting a candidate RNA-binding protein, mutating the CRD itself, or tagging the protein at its endogenous locus can reveal whether the interaction is required for transcript stability and downstream phenotypes. These approaches are particularly useful when combined with reporter assays and RNA stability measurements.

Proteomic and bioinformatic tools complement RNA-level studies by identifying protein networks that change when CRD-mediated stabilization is perturbed. Comparative proteomic analysis of bortezomib resistance in prostate cancer cells illustrates how such approaches can reveal resistance-associated pathways. Similar strategies can be applied to CRD-related models to connect mRNA stability to protein-level outcomes.

Researchers studying CRD-mediated mRNA stabilization-related genes often need to determine whether a candidate gene is causally involved in transcript stability, whether a specific CRD sequence is required, and how the process behaves in disease-relevant cell models. Answering these questions requires precise, reproducible genome engineering and functional readouts.

GO:0070934, CRD-mediated mRNA stabilization, defines a post-transcriptional mechanism in which RNA-binding proteins recognize a coding region instability determinant and protect the mRNA from decay. The c-myc system, where IGF2BP1-associated cytoplasmic RNPs control mRNA stability, remains the foundational example, while broader studies in cervical cancer, oral squamous cell carcinoma and drug resistance illustrate the wider relevance of post-transcriptional control in disease. Because the process depends on specific RNA-protein interactions, it is well suited to CRISPR-based functional dissection and to integrated RNA, protein and bioinformatic analysis.